# Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-reports-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: TSHA
Company: Taysha Gene Therapies
Source: Taysha Gene Therapies
Published: 2026-05-06 12:00 EST
Original Source URL: https://ir.tayshagtx.com
## Summary

Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting   Further advanced dosing in the REVEAL pivotal trial, with

## Article Body
Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting   Further advanced dosing in the REVEAL pivotal trial, with
## Recent Company News
- 2026-05-06 12:00 EST — [Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Taysha Gene Therapies
- 2026-05-01 20:05 EST — [Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Taysha Gene Therapies
- 2026-04-29 12:00 EST — [Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6) — Source: Taysha Gene Therapies
- 2026-04-27 21:22 EST — [Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-present-new-preclinical-data-supporting-construct-design-of-tsha-102-for-rett-syndrome-at-the-asgct-2026-annual-meeting) — Source: Taysha Gene Therapies
- 2026-03-19 12:00 EST — [Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-reports-full-year-2025-financial-results-and-provides-corporate-update) — Source: Taysha Gene Therapies
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)